Haynes Boone advised on the signing of a merger agreement between Pulmatrix, Inc. and Eos SENOLYTIX, Inc., a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases. Haynes Boone also advised on a concurrent private financing of PULM in connection with the merger.
Under the terms of the agreement, Pulmatrix will acquire Eos, with the combined company expected to operate under the Eos name and trade on Nasdaq under the ticker symbol EOSX. The combined company will focus on advancing therapies designed to address age-related diseases, including sarcopenia and obesity, through novel approaches targeting mitochondrial function and cellular aging.
The Haynes Boone deal team was led by Partners Rick Werner, Alla Digilova and Simin Sun, with support from Associates Lisa Vasek, Victoria Lee and Brent Duddles.
In connection with the merger, PULM and Eos also entered into definitive agreements for a concurrent private financing expected to generate approximately $19.0 million in gross proceeds. The financing includes participation from a syndicate of healthcare investors and is expected to support advancement of the company’s proprietary mitochondrial-focused therapeutic platform, including its lead clinical candidate.
The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in mid-2026, subject to customary closing conditions, including stockholder approvals and regulatory filings.
